Coronary IVL: what comes after trial enrolment?

For interventional teams following calcium-modification research, completing enrolment is a reason to open an evidence file, not close a purchasing decision. This week's retrospective selection is TECTONIC: an investigational coronary intravascular lithotripsy programme for which the sponsor confirms that recruitment is complete. The distinction between a development milestone and a clinical result is the central point of this review. ^[1]

What happened

An announcement dated 4 August, subsequently reported on 6 August, described completion of enrolment in the TECTONIC CAD IVL study. It reported 335 participants across 40 US clinical sites and anticipated an initial presentation at TCT later in the year. Those are enrolment and scheduling statements; they are not efficacy estimates, safety rates or evidence of an achieved study endpoint. ^[2]

Abbott describes SonicForce as an investigational balloon-catheter system that uses acoustic energy to modify coronary calcium before stent placement. The sponsor's page states that the device is investigational in the United States and is not commercially available outside it. Aperture Science makes no distribution or endorsement claim for this technology. ^[1]

“Patient enrollment is complete for the TECTONIC clinical trial.” — Abbott's study information page. ^[1]

What the announcement does not answer

Our editorial priority is the eventual endpoint report. We would want the precise primary endpoint definition, the denominator used for each analysis, follow-up completeness, adverse-event adjudication and the prespecified statistical framework beside any headline result. No effect size, confidence interval or p-value is supplied in this article because no verified endpoint results were available in the source material reviewed.

A useful review file could begin with two separate pages: one for the protocol and another for results when published. That separation would make it harder to mistake a planned sample, anticipated endpoint or sponsor aspiration for an observed outcome. The public study record is linked for that purpose; this milestone report is not an appraisal of the full protocol or eventual study results. ^[3]

Questions for the full readout

Which lesion characteristics define the studied population? Which patients or anatomies were excluded? What would constitute procedural success, and what would qualify as a safety event? Were analyses planned before recruitment finished? Are all enrolled participants accounted for, including unsuccessful procedures and incomplete follow-up? These are proposed appraisal questions, not assertions about deficiencies in TECTONIC.

We would also distinguish the immediate procedural question from the later clinical question. A presentation might contain several kinds of endpoint; our review would keep each attached to its own definition and observation period. We would not translate a procedural measurement into a mortality benefit or use a subgroup estimate to make a claim about every patient. That is an editorial boundary, not a prediction about the trial.

A South African evaluation file

For a South African clinical or procurement committee, our proposed next step is documentary preparation. A review folder could contain the study registration, eventual primary paper, supplementary methods, applicable instructions for use and independently checked local availability information. The research discussion and the commercial assessment should remain visibly separate in that folder.

Questions for any future local proposal might include which team would assess the evidence, which clinical question the proposed technology addresses, and which existing internal approval process would apply. These questions do not presume that the investigational system will become available locally. They also do not imply that Aperture Science currently imports, supports, stocks or recommends it.

Operational questions belong in a later assessment, not in an inferred clinical claim. If a locally available system were ever proposed, the committee could ask for documented training requirements, service arrangements, traceability processes, compatible equipment and the proposed method for reviewing incidents. Our article does not supply those details and does not assume that information about one device transfers to another.

How we would report the data

We would begin the eventual results article with the clinical question and study design, followed by the population, endpoints and uncertainty. If a prespecified endpoint were met, the report would say which endpoint; if it were not met, that would receive equal prominence. Missing follow-up and exploratory analyses would be identified rather than absorbed into a general conclusion.

Any investigator comment would be attributed to a named source and placed beside the actual findings. We would not manufacture a quotation to make the article feel authoritative. The sponsor statement above documents study progress only; it should not be read as independent expert validation. This distinction also matters when a trial presentation is subsequently revised in a peer-reviewed publication.

What to watch next

The next useful update is a verifiable endpoint report with enough methodological detail to assess what was studied and what was observed. Our editorial watch list is the primary publication, complete safety tables, prespecified analyses and any documented change in the study's status. The links below provide a starting point, not a completed clinical appraisal.

Until those materials have been reviewed, the appropriate description in this journal is a trial milestone. Readers can follow the programme without equating interest with endorsement, assuming local availability, or treating a forthcoming conference presentation as evidence that a clinical question has already been answered.